
feb pm et
summari lead manufactur develop analyt laboratori instrument
suppli life scienc drug discoveri industri applic
price-to-earnings oper ep
geograph coverag spread across life scienc
health care industri market think
reduc risk howev proactiv acquisit
strategi rais risk profil
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview novemb thermo electron corp fisher scientif complet
stock-for-stock merger combin compani renam thermo fisher scientif
lead provid life scienc laboratori analyt instrument equip reagent
consum softwar servic research analysi discoveri diagnosi major end-market
immunohistochemistri cell screen environment regulatori complianc food safeti think
market repres combin billion billion annual marketplac think
largest compani within marketplac broadest product offer geograph coverag
sinc merger complet numer addit acquisit see corpor strategi section
thermo electron busi focus primarili develop manufactur analyt
system instrument compon provid solut monitor collect analyz data
instrument use primarili life scienc drug discoveri clinic environment industri
laboratori applic fisher scientif busi focus provid broad rang
scientif research health care safety-rel product servic custom includ
pharmaceut biotechnolog compani colleg univers medic research institut
hospit refer lab research develop lab
compani follow acquisit februari report four busi
segment life scienc solut sale specialti
diagnost laboratori product servic life scienc solut compris
primarili busi focus genet sequenc instrument servic
analyt technolog focus scientif instrument bioscienc reagent lab informat
autom environment monitor instrument industri process instrument analyt
technolog compris primarili legaci thermo electron busi specialti diagnost focus
diagnost instrument assay laboratori product servic compris primarili legaci
fisher scientif busi focus lab equip consum biopharma outsourc
corpor strategi think strength lie extens product offer geograph
coverag one-stop shop strategi allow scientist research health care profession
order divers product need time cost-effect manner one sourc
continu expand product portfolio extens intern develop extern
growth via acquisit recent notabl acquisit includ august acquisit patheon
billion septemb acquisit fei compani billion march
acquisit affymetrix billion februari acquisit
billion lead provid life scienc tool servic includ next gener sequenc
august acquisit phadia ab sweden-bas global leader in-vitro allergi diagnost
may acquisit dionex lead provid chromatographi instrument signific
presenc asia juli acquisit fermenta manufactur global distributor
enzym reagent kit molecular cellular biolog research march acquisit
finnzym provid integr tool molecular biolog analysi includ reagent instrument
consum kit februari acquisit ahura scientif provid handheld
spectroscopi instrument use world-wide identif chemic safeti secur
pharmaceut applic octob acquisit ag lead provid
specialti diagnost test base patent biomark sepsi cardiovascular pulmonari
diseas well intens care treatment prenat screen april acquisit
biolab australia-bas provid analyt instrument life scienc consum laboratori
competit landscap life scienc tool servic scientif product servic
marketplac highli fragment highli competit think may competit advantag
peer due purchas power oper leverag broad product offer
corp water corp among privat held firm primari competitor
financi trend forma sale increas billion billion
repres compound annual growth rate compound-annual-growth-rate prolif acquir acquisit
aid sale growth howev compani also streamlin variou oper
divest busi well adjust oper margin increas
adjust ep rose repres compound-annual-growth-rate
board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month may congress
approv billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
howev note mani life scienc
compani activ pursu initi
commerci non-academ govern
revenu base also see budget issu
europ result soft govern fund
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain initi
support alzheim diseas research
overal see mid-single-digit sale growth
emerg market
china remain robust growth region
grow double-digit rate help fuel
overal industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
 composit index year date
decemb life
rise composit
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
offer believ deal accret first year close
et cfra reiter strong buy opinion share thermo
fisher scientif rais target
slightli peer next ep estim
discount growth via acquisit nonetheless posit view
growth strategi well-diversifi product mix ep vs
ahead estim rais ep estim
respect sale rose organ growth
oper margin rose rais sale guidanc
ep
thermo fisher scientif inc announc elect dion weisler
board director effect march mr weisler appoint
bring total number thermo fisher board member mr weisler
presid chief execut offic hp inc sinc novemb
follow separ hewlett-packard two independ compani
also serv board director prior mr weisler
execut vice presid hewlett-packard print person
system busi four year
target ep estim in-lin peer
expect report sale growth inclus
affymetrix fei acquisit aid growth china see modest growth
largest unit laboratori product amid tighten hospit capit
budget expect oper margin
captur market share high-margin genet
sequenc segment realiz acquisit synergi replac
constel brand inc portfolio /k snyder
analyst research note compani news
fisher scientif rais target
slightli peer ep estim
set ep vs ahead
estim sale rose organ growth saw broad-bas product
geograph growth biopharma market grew govt/academ
diagnost rose high-singl digit industri rose mid-singl
digit expect oper margin declin lower pantheon
margin see leverag synergist benefit aid margin
et cfra reiter buy opinion share
thermo fisher scientif announc
deal enabl sell ion ampliseq technolog research
util next-gener sequenc platform sell
product name ampliseq continu
sell custom share rose significantli follow
announc deal two largest firm genet
sequenc space rais possibl partnership rais
target peer ep estim
et cfra keep strong buy opinion share thermo fisher
scientif inc rais target
peer forward ep estim
discount growth acquisit ep vs
ahead estim rais ep estim
reflect recent acquisit patheon sale
rose organ growth encourag sale growth
note oper margin fell lower patheon margin still
believ leverag improv margin well synergist benefit
et cfra reiter strong buy opinion share thermo
fisher scientif rais target
below-p forward ep estim
discount growth via acquisit ep vs
ahead estim rais ep estim sale
rose organ growth pharma biotech end-market remain
strong see gain market share chemic market continu
show sign improv rais sale guidanc
lower end ep rang
/jeffrey loo cfa
juli board director thermo fisher scientif inc
appoint mark stevenson execut vice presid chief oper
offic effect august new role mr stevenson
oper oversight compani laboratori product analyt
instrument busi addit current respons life
scienc solut busi mr stevenson appoint execut vice
presid presid life scienc solut februari upon
compani acquisit life technolog corpor also juli
thoma loewald name execut offic compani notifi
compani decis resign effect septemb
et cfra reiter strong buy opinion share thermo
fisher scientif agre acquir patheon nv
pthn nr share inclus net debt pthn
contract develop manufactur organ assist
biopharmaceut firm complex develop manufactur need
forecast sale ebitda
think pay premium ev/ebitda see signific
synergi believ pthn expand end-to-end product servic
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
